A Randomized, Comparative Study of Rabeprazole vs. Ranitidine Maintenance Therapies for Reflux Esophagitis: Multicenter Study.
- Author:
Sam Ryong JEE
1
;
Sang Young SEOL
;
Do Ha KIM
;
Seun Ja PARK
;
Sang Young HAN
;
Sang Hwa URM
;
Jong Tae LEE
Author Information
1. Department of Internal Medicine, Inje University College of Medicine, Paik Hospital, Busan, Korea. seolsymd@hanmail.net
- Publication Type:Original Article ; Comparative Study ; English Abstract ; Multicenter Study ; Randomized Controlled Trial
- Keywords:
Maintenance therapy;
Reflux esophagitis;
Rabeprazole;
Ranitidine
- MeSH:
2-Pyridinylmethylsulfinylbenzimidazoles;
Adult;
Anti-Ulcer Agents/*therapeutic use;
Benzimidazoles/*therapeutic use;
Esophagitis, Peptic/*drug therapy;
Female;
Humans;
Male;
Middle Aged;
Omeprazole/*analogs & derivatives/therapeutic use;
Ranitidine/*therapeutic use
- From:The Korean Journal of Gastroenterology
2005;45(5):321-327
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Reflux esophagitis is a recurring condition for which many patients require maintenance therapy. This comparative, randomized multicenter study was designed to evaluate the effect of long-term maintenance treatment comparing proton pump inhibitor, rabeprazole and H2 receptor antagonist, ranitidine. METHODS: Eighty four patients with healed reflux esophagitis confirmed by endoscopy were randomly allocated to receive maintenance treatment with either rabeprazole 10 mg once daily or ranitidine 300 mg once daily for 32 weeks. Patients were seen every 8 weeks or at symptomatic relapse. RESULTS: Of 84 initially treated patients, 73 entered the maintenance study. The percentage of asymptomatic patients after 90-day and 210-day treatment were 97% and 81.5%, for rabeprazole and 74.3% and 62.3%, for ranitidine, respectively. After 32 weeks, the relapse rates of esophagitis were 21.3% in the rabeprazole group and 62.9% in the ranitidine group (RR: 0.405, 95% CI: 0.215-0.766). CONCLUSIONS: Maintenance treatment with rabeprazole (10 mg once daily) is superior to ranitidine (300 mg once daily) in keeping the patients with reflux esophagitis in remission over a 32 week period.
